

The Virtual Assessment in Lewy Body Dementia: Pandemic and Beyond Webinar Series

Needs Assessment The COVID-19 pandemic necessitated transition of care to telemedicine due to public health concerns. Those with LBD represent a population vulnerable to the complications of COVID-19 given advanced age and the clinical features inherent to LBD. While the call for telemedicine during COVID-19 is clear, it is less clear how in-office diagnosis and care translates to virtual care in this population.

Target Audience This webinar series is intended for healthcare professionals engaged in the care of patients living with Lewy body dementia and who wish to address this need.

Webinar #3: Impact of COVID-19 in those with LBD

Date: May 27, 2021 Time: 10am EST/3pm UTC

Register now!

Presenter: JP Taylor, PhD

Institute of Neuroscience, Biomedical

Research

Campus for Ageing and Vitality Newcastle University, Newcastle Panel Discussant: Jennifer Goldman.

MD, MS

Shirley Ryan AbilityLab and

Northwestern University Feinberg School Westchester Medical Center

of Medicine,

Chicago, IL

Panel Discussant: Katherine

Amodeo, MD

Department of Neurology,

Poughkeepsie, NY

At the conclusion of the activity, learners should be able to:

- Analyze data on recent survey regarding the impact of COVID on LBD population.
- Review LBD and its clinical features, "what you should know" and what to be aware of.
- Discuss why this population is particularly at risk for complications of COVID-19.



Accreditation Statement In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Lewy Body Dementia Association. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the

Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



Designation Statement Postgraduate Institute for Medicine (PIM) designates this internet live activity for a maximum of 1.0 (one) AMA PRA Category 1 credit™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Allied healthcare professionals Participants will receive a Certificate of Attendance stating this program is designated for 1.0 (one) AMA PRA Category 1 Credit™. This credit is accepted by the AANP and the AAPA.

ABPN Approval for Neurologists and Psychiatrists The American Board of Psychiatry and Neurology has reviewed the webinar "Impact of COVID-19 in those with LBD" and has approved this program as part of a comprehensive CME program, which is mandated by the ABMS as a necessary component of Maintenance of Certification.

This activity is supported by an educational grant by Acadia Pharmaceuticals Inc. There is no fee for this educational activity.

Disclosure of Conflicts of Interest Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.